Acquired thrombotic thrombocytopenic purpura and pregnancy: More light than shade but controversies remain

Jaume Alijotas-Reig

doi:10.1016/j.thromres.2017.07.005

Acquired thrombotic thrombocytopenic purpura and pregnancy: More light than shade but controversies remain

Jaume Alijotas-Reig

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Thrombotic thrombocytopenic purpura (TTP) is an acute, rare and potentially life-threatening, thrombotic microangiopathy (TMA) characterised clinically by the pentad of fever, microangiopathic haemolytic anaemia, thrombocytopenia, renal involvement and brain dysfunction, with severe deficiency (]. Plasma-based therapy comprising the replacement of ADAMTS-13 together with high-dose i.v. methylprednisolone is the mainstay of treatment for TTP.

Original language	English
Pages (from-to)	195-197
Number of pages	3
Journal	Thrombosis Research
Volume	156
DOIs	https://doi.org/10.1016/j.thromres.2017.07.005
Publication status	Published - Aug 2017

Keywords

ADAM Proteins
Female
Humans
Light
Plasma Exchange
Pregnancy
Pregnancy Complications, Hematologic
Purpura, Thrombotic Thrombocytopenic

Access to Document

10.1016/j.thromres.2017.07.005Licence: C In Copyright

Cite this

@article{ef5d2949631d4b7197dddc596b96cddc,

title = "Acquired thrombotic thrombocytopenic purpura and pregnancy: More light than shade but controversies remain",

abstract = "Thrombotic thrombocytopenic purpura (TTP) is an acute, rare and potentially life-threatening, thrombotic microangiopathy (TMA) characterised clinically by the pentad of fever, microangiopathic haemolytic anaemia, thrombocytopenia, renal involvement and brain dysfunction, with severe deficiency (]. Plasma-based therapy comprising the replacement of ADAMTS-13 together with high-dose i.v. methylprednisolone is the mainstay of treatment for TTP.",

keywords = "ADAM Proteins, Female, Humans, Light, Plasma Exchange, Pregnancy, Pregnancy Complications, Hematologic, Purpura, Thrombotic Thrombocytopenic",

author = "Jaume Alijotas-Reig",

year = "2017",

month = aug,

doi = "10.1016/j.thromres.2017.07.005",

language = "English",

volume = "156",

pages = "195--197",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Acquired thrombotic thrombocytopenic purpura and pregnancy

T2 - More light than shade but controversies remain

AU - Alijotas-Reig, Jaume

PY - 2017/8

Y1 - 2017/8

N2 - Thrombotic thrombocytopenic purpura (TTP) is an acute, rare and potentially life-threatening, thrombotic microangiopathy (TMA) characterised clinically by the pentad of fever, microangiopathic haemolytic anaemia, thrombocytopenia, renal involvement and brain dysfunction, with severe deficiency (]. Plasma-based therapy comprising the replacement of ADAMTS-13 together with high-dose i.v. methylprednisolone is the mainstay of treatment for TTP.

AB - Thrombotic thrombocytopenic purpura (TTP) is an acute, rare and potentially life-threatening, thrombotic microangiopathy (TMA) characterised clinically by the pentad of fever, microangiopathic haemolytic anaemia, thrombocytopenia, renal involvement and brain dysfunction, with severe deficiency (]. Plasma-based therapy comprising the replacement of ADAMTS-13 together with high-dose i.v. methylprednisolone is the mainstay of treatment for TTP.

KW - ADAM Proteins

KW - Female

KW - Humans

KW - Light

KW - Plasma Exchange

KW - Pregnancy

KW - Pregnancy Complications, Hematologic

KW - Purpura, Thrombotic Thrombocytopenic

U2 - 10.1016/j.thromres.2017.07.005

DO - 10.1016/j.thromres.2017.07.005

M3 - Article

C2 - 28697902

SN - 0049-3848

VL - 156

SP - 195

EP - 197

JO - Thrombosis Research

JF - Thrombosis Research

ER -

Acquired thrombotic thrombocytopenic purpura and pregnancy: More light than shade but controversies remain

Abstract

Keywords

Access to Document

Fingerprint

Cite this